Patents Represented by Attorney Keith R. Lange
-
Patent number: 7938776Abstract: The present invention describes examination devices, such as examination gloves, for detecting the presence of blood, and in particular hidden blood, in biological samples. Examination devices according to the present invention include, in certain embodiments, developer and indicator reagents in a single encapsulation, which offers numerous clinical and other benefits. Kits including devices according to the present invention in sterile packaging, and methods of making and using devices according to the present invention, are also described.Type: GrantFiled: March 18, 2008Date of Patent: May 10, 2011Assignee: Mederistic Solutions, Inc.Inventors: Albert T. Barnes, Sr., Albert T. Barnes, Jr.
-
Patent number: 7759317Abstract: The present invention relates to pharmaceutical compositions containing certain flavonoid glycoside-type compounds that have been shown in the present invention to be therapeutically useful, including useful as analgesics and anti-inflammatories for the treatment and management of pain and inflammatory conditions. Methods for the therapeutic uses of such compounds and pharmaceutical compositions is also provided.Type: GrantFiled: December 28, 2007Date of Patent: July 20, 2010Assignee: BMB Patent Holding CorporationInventor: Barry Miles Belgorod
-
Patent number: 7391424Abstract: Techniques and systems for production of composite images, videos, or films which exhibit virtual objects. More particularly, techniques and systems for rendering, scaling, and/or locating, virtual objects within composite images, videos, or films employing marker objects as reference objects. In at least one embodiment, a virtual object is rendered by synchronizing a virtual camera with a real camera and, subsequently, synthesizing a canvas featuring the virtual object at a position determined in reference to the position of a detected marker object.Type: GrantFiled: August 15, 2003Date of Patent: June 24, 2008Inventor: Werner Gerhard Lonsing
-
Patent number: 7049412Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.Type: GrantFiled: August 9, 2000Date of Patent: May 23, 2006Assignee: Bristol-Myers Squibb Pharma Comp.Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
-
Patent number: 6942990Abstract: The invention provides a glutaryl 7-ACA amidase from Pseudomonas diminuta strain BS-203, which catalyzes the hydrolysis of 7-?-(4-carboxybutanamido)-cephalosporanic acid to 7-aminocephalosporanic acid and glutaric acid. The invention also provides nucleic acid sequences, vectors, and host cells useful in the production of this amidase. The glutaryl 7-ACA amidase can be used for the preparation of 7-aminocephalosporanic acid.Type: GrantFiled: January 17, 2003Date of Patent: September 13, 2005Assignee: Bristol Myers Squibb CompanyInventors: Ross Binder, Joanne L. Brown, Thomas J. Franceschini, William V. Burnett, Michael Politino, Suo Win Liu, Sean M. Tonzi
-
Patent number: 6770876Abstract: The present invention relates to an autosampler device useful in high pressure liquid chromatography (HPLC), and more particularly to a device useful for the automated introduction of small sample volumes into a HPLC system. Methods of analyzing low abundant protein samples using such a device are also included.Type: GrantFiled: April 11, 2003Date of Patent: August 3, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Ming Gu, Wenjeng Li, John W. Allen
-
Patent number: 6759509Abstract: Conjugates containing a targeting ligand, such as an antibody, a therapeutically active drug and a branched peptide linker. The branched peptide linker contains two or more amino acid moieties that provide an enzyme cleavage site. The number of drugs capable of being bonded to the branched linkers varies by a factor of two for each generation of branching.Type: GrantFiled: October 31, 1997Date of Patent: July 6, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Dalton King, Raymond A. Firestone, Gene M. Dubowchik
-
Patent number: 6753176Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.Type: GrantFiled: September 19, 2002Date of Patent: June 22, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
-
Patent number: 6699715Abstract: The modified sFv molecules of the present invention stimulate adhesion between cells thereby enhancing the immune response against disease. These molecules generally comprise an antigen binding site of an antibody and at least a portion of a transmembrane domain of a cell surface receptor.Type: GrantFiled: November 27, 1996Date of Patent: March 2, 2004Assignee: Bristol-Myers Squibb Co.Inventors: Jeffrey A. Ledbetter, Martha Hayden, Perry Fell, Robert Mittler, Gosta Winberg
-
Patent number: 6538103Abstract: The present invention concerns peptide fragments of angiostatin containing lysine-binding sites of angiostatin which can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that involves angiogenesis. The lysine binding fragments are derived from kringles 1,2 and/or 4 of plasminogen.Type: GrantFiled: July 7, 1999Date of Patent: March 25, 2003Assignee: Bristol--Myers Squibb CompanyInventors: Richard Wei-Dong Ji, Pamela A. Trail
-
Patent number: 6521436Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.Type: GrantFiled: August 9, 2000Date of Patent: February 18, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
-
Patent number: 6512101Abstract: Branched hydrazone linkers for linking a targeting ligand such as an antibody to a therapeutically active drug. The point of branching is at a polyvalent atom and the number of drugs increases by a factor of two for each generation of branching. A preferred drug is doxorubicin.Type: GrantFiled: August 19, 1998Date of Patent: January 28, 2003Assignee: Bristol Myers Squibb CompanyInventors: Dalton King, Raymond A. Firestone, Pamela Trail
-
Patent number: 6384198Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric nonclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional non-HIV-1-producing T cells in the patient.Type: GrantFiled: May 31, 1995Date of Patent: May 7, 2002Assignee: Bristol-Myers Sqibb CompanyInventors: Michael L Diegel, Peter S Linsley, Lisa K Gilliland, Patricia A Moran, Joyce M Zarling, Jeffrey A Ledbetter